ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1570

Memory CD4+T Cell Signature Is Associated with Unfavorable Prognosis in IgG4-related Disease: Risk Stratification by Machine-learning

Yuxue Nie1, zheng liu1, Wei Cao2, Taisheng Li2 and Wen Zhang3, 1Department of Rheumatology, Peking Union Medical College Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, 2Department of Infectious Diseases, Peking Union Medical College Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, 3Peking Union Medical College Hospital, Beijing, China

Meeting: ACR Convergence 2022

Keywords: IgG4 Related Disease, immunology, T Cell

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Vasculitis – Non-ANCA-Associated and Related Disorders Poster II

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: IgG4-related disease (IgG4-RD) is a chronic immune-mediated disease with significant heterogeneity. A better understanding of the variance in the immune signature of IgG4-RD will contribute to the treatment of IgG4-RD. In this study, we used machine-learning approaches to demostrate the immune cell profiles and identify the heterogeneity of IgG4-RD.

Methods: Demographic and clinical data of IgG4-RD patients (2019 ACR/EULAR classification criteria) including organ involvement, disease activity (Responder Index) and laboratory tests, were collected respectively. The immunophenotype of PBMC of IgG4-RD patients and healthy controls (HCs) was determined by flow cytometry and univariate analysis to compare percentages of immune cell subsets between IgG4-RD and HCs. EXtreme Gradient Boosting (XGBoost) was applied for the construction of the classification model between IgG4-RD and HCs. To visualize the importance of the features in the XGBoost model, SHapley Additive exPlanations (SHAP) value in the model was shown. K-means clustering with the proportions of T cell subsets and NK cells to identify the heterogeneity of IgG4-RD. Kaplan-Meier analysis and logistic regression were used to investigate the prognosis and potential risk factors for the likelihood of relapse in IgG4-RD. This study was approved by the Ethics Committee of Peking Union Medical College Hospital (PUMCH).

Results: This study included 148 patients with IgG4-RD (median [IQR] age 56.0 [46.8, 63.0] years, 57.4% male) and 188 sex/age-matched HCs. The median follow-up time of those patients was 12 months (IQR [6–12] months). The XGBoost model discriminated patients with IgG4-RD from HCs with an area under the receiver operating characteristic curve (AUC) of 0.963 in the testing set. The top three features identified by SHAP value in the XGBoost model were naïve CD4+T, DR+CD8+T, and CD4+T cells. By K-means clustering, IgG4-RD patients were classified into two clusters. Cluster 1 (N = 99) featured a higher proportion of memory CD4+T cells, and cluster 2 (N = 49) featured a higher proportion of naïve CD4+T cells accordingly. The two clusters shared similar clinical characteristics and the initial or maintenance treatment. The unfavorable prognosis was defined as relapse of IgG4-RD or the decision of enhancing treatment intensity (increased dose of glucocorticoids or switch to more powerful immunosuppressors) by experts in rheumatology during the follow-up visits. In the Kaplan-Meier analysis, cluster 1 was more likely to have an unfavorable prognosis in the follow-up. Furthermore, in the multivariate logistic regression, cluster 2 was shown to be a protective factor.

Conclusion: Immune cell signature with machine-learning approaches was efficient in the discrimination of IgG4-RD patients and HCs. Immunophenotyping of IgG4-RD may help in the identification of patients with the potential to relapse and attention should be paid to those patients with elevated proportions of memory CD4+T cells.


Disclosures: Y. Nie, None; z. liu, None; W. Cao, None; T. Li, None; W. Zhang, None.

To cite this abstract in AMA style:

Nie Y, liu z, Cao W, Li T, Zhang W. Memory CD4+T Cell Signature Is Associated with Unfavorable Prognosis in IgG4-related Disease: Risk Stratification by Machine-learning [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/memory-cd4t-cell-signature-is-associated-with-unfavorable-prognosis-in-igg4-related-disease-risk-stratification-by-machine-learning/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/memory-cd4t-cell-signature-is-associated-with-unfavorable-prognosis-in-igg4-related-disease-risk-stratification-by-machine-learning/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology